Week Ending April 25, 2022

COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery
“Lung cancer patients have been associated with an increased risk of COVID-19 infection, pulmonary complications, and worse survival outcomes compared to the general population.”

Trastuzumab Deruxtecan Granted Priority Review by FDA for Previously Treated HER2-Mutant Metastatic NSCLC
“Patients with HER2-mutated metastatic non–small cell lung cancer who have previously received treatment with systemic therapies appear to benefit from treatment with fam-trastuzumab deruxtecan-nxki, which received priority review from the FDA.”

Access to Quality Lung Cancer Care
“When you have lung cancer, having access to high-quality health care is vitally important. Access to care is defined as “the timely use of personal health services to achieve the best health outcomes.”1

The New Tool in the Fight Against Lung Cancer
“There have been significant developments over the last decade when it comes to the treatment of lung cancer. One of those developments has been the use of immunotherapy.”

Black Veterans receive equal, or superior, lung cancer care in VA
“Black Veterans with lung cancer receive comparable care, with equivalent, if not superior, treatment outcomes as white Veterans at VA, according to a study by VA St. Louis researchers. VA cancer care appears to be more equitable than care received in the private sector, where significant racial disparities exist.”

Certain patients may derive more benefit from immunotherapy for non-small cell lung cancer
“Men, smokers and younger patients with non-small cell lung cancer all appeared to derive more benefit from immunotherapy, according to a systematic review published in JNCI Cancer Spectrum.

A Year of Lung Cancer Improvements, With More Work To Do

EGFR Exon 20 Insertion–Positive NSCLC: Overview of Treatment Options